None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria were as follows: (1) leukemia, lymphoma, or multiple myeloma patients who are scheduled to receive autologous HSCT, allogeneic HSCT, or half-allogeneic HSCT, (2) between 18 and 65 years of age, (3) ability to understand and provide written informed consent in Korea, (4) no evidence of cardiac or pulmonary failure associated with treatment.
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: (1) existing evidence of recurrent or metastatic disease, (2) pregnant or planned to be pregnant within six month, (3) any condition unsuitable for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;feasibility;body composition;Physical function | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom;Amout of transfusion and platelet engraftment | — |
Countries
Korea, Republic of
Contacts
Yonsei University